Skip to content Skip to menu

Medicines industry acknowledges contribution of Senator Kim Carr

Monday, 5 March 2012

Media Release

Medicines Australia chief executive Dr Brendan Shaw has congratulated the outgoing Minister for Manufacturing Senator Kim Carr on his legacy of achievement and contribution to industry and innovation policy.

Senator Carr was today sworn in as Minister for Human Services, after four and a half years as Minister for Innovation, Industry, Science and Research and latterly Minister for Manufacturing.

Dr Shaw said Senator Carr had been a consistently passionate advocate for industry generally, and for the Australian medicines industry in particular.

“Senator Carr has long been committed to maintaining and growing an innovative industrial base in Australia and has made a positive contribution to ensuring a viable operating environment for the Australian medicines industry,” Dr Shaw said.

“He has led the clinical trials reform agenda which seeks to ensure that Australia remains competitive in attracting global investment in clinical trials.

“The R&D tax credit legislation, which he stewarded through Parliament, will effectively reduce by 10 per cent the cost of conducting eligible R&D in Australia.

“Senator Carr has also advocated the importance of patent protection, and championed the Raising the Bar Bill, which is currently before the Parliament and which will bring Australia’s intellectual property regime into line with world standards.

“And he established the Pharmaceuticals Industry Strategy Group to develop a blueprint for a sustainable pharmaceuticals industry in Australia.

“I congratulate him on this record of achievement during his time in the Innovation and Manufacturing portfolios and I look forward to working with him as the new Minister for Human Services.”


Contact Person:

Jamie Nicholson
Media Communications Manager
Phone: 0419 220 293


As COVID19 continues to spread, our thoughts go out to anyone who has been infected or impacted. We hope that you are taking the necessary precautions to keep safe and well, both at work and at home.

Medicines Australia continues to monitor the situation and take advice from the Department of Health and the World Health Organisation. We are focused on responding to the important short-term issues but are also ensuring we stay balanced and maintain a focus on the medium and long-term business for our industry along with the well-being of our people.

At Medicines Australia we have initiated the following to ensure we support containment measures to provide business continuity and the well-being of our staff.

  • All non-essential travel has been restricted or cancelled
  • All face-to-face meetings (with external stakeholders and members) have been changed to virtual meetings (where appropriate)
  • Staff have been provided with the latest official information on COVID-19 through a hot-link on the office intranet; this information is regularly monitored and updated
  • Flexible working arrangements are covered in our HR policy which will allow staff to work remotely, if or when required
  • Current IT infrastructure enables staff to work remotely and will be in use if any person needs to self-isolate
  • Visual reminders have been displayed around the office, providing information about best hygiene practices
  • Extra hand-sanitiser, tissues and cleaning products have been supplied to staff for their work spaces

Our latest information is located at